Pharmacist-led screening for mental illness: A systematic review

被引:0
|
作者
Ou, Kevin [1 ]
Gide, Duha N. [2 ]
El-Den, Sarira [2 ]
O'Donnell, Lisa Kouladjian [3 ]
Malone, Daniel T. [4 ]
O'Reilly, Claire L. [2 ]
机构
[1] Pharmaceut Soc Australia, Sydney, NSW, Australia
[2] Univ Sydney, Fac Med & Hlth, Sydney Pharm Sch, Sydney, NSW, Australia
[3] Royal North Shore Hosp, Kolling Inst Med Res, Clin Pharmacol & Ageing, St Leonards, NSW, Australia
[4] Monash Univ, Fac Pharm & Pharmaceut Sci, Melbourne, Vic, Australia
来源
关键词
Mental disorders; Pharmacists; Screening; Early identification; COMMUNITY PHARMACY; DEPRESSION SCREENINGS; BRIEF INTERVENTION; RISK-ASSESSMENT; HEALTH; PILOT; IMPLEMENTATION; DISORDERS; SERVICES; OUTCOMES;
D O I
10.1016/j.sapharm.2024.06.001
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Early identification and treatment of mental illnesses is imperative for optimal patient outcomes. Pharmacists may play an important role in mental healthcare through the provision of screening services for mental illnesses. Objective: (s): : To systematically review the impact of pharmacist-led mental illness screening on clinical or patient-reported outcomes and identify and report any follow-up or referral systems used in pharmacist-led screening interventions for mental illnesses. Methods: A systematic review was conducted by searching MEDLINE, CINAHL, Embase and APA PsycInfo via EBSCOhost from inception to 9 March 2023 to identify studies involving pharmacist-led screening interventions for mental illnesses. Data was collected on the mental illness in question, setting and population characteristics, screening tools used, clinical or patient-reported outcomes, and follow-up and referral systems reported. Results: Twenty six studies were identified that related to screening for mental illnesses, such as depressive disorders and substance use disorders. There were a variety of study designs, including uncontrolled studies (n = 23), pre-post studies (n = 2) and randomised controlled trials (n = 1). Screening was conducted in different settings, with most studies conducted in community pharmacies (n = 21/26, 87.8 %) and focusing on depression screening (n = 12/26, 46.1 %). A range of follow-up and referral methods to other healthcare professionals were reported, including verbal (n = 3/26, 11.5 %), both written and verbal (n = 3/26, 11.5 %), communications via electronic health record (n = 2/26, 7.7 %) and written (n = 1/26, 3.8 %). Conclusions: Pharmacists provide screening for a variety of mental illnesses in different settings. Various referral methods and follow-up pathways may be utilised for post-screening patient care. However, current evidence is insufficient to establish improvements in early detection, treatment, or outcomes. Further large, well-designed studies are required to support the role of pharmacists in mental illness screening, provide evidence on the impact of pharmacist-led mental illness screening services and inform the most effective follow up and referral methods.
引用
收藏
页码:828 / 845
页数:18
相关论文
共 50 条
  • [1] Pharmacist-led interventions for people living with severe and persistent mental illness: A systematic review
    Ng, Ricki
    El-Den, Sarira
    Stewart, Victoria
    Collins, Jack C.
    Roennfeldt, Helena
    McMillan, Sara S.
    Wheeler, Amanda J.
    O'Reilly, Claire L.
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2022, 56 (09): : 1080 - 1103
  • [2] Stakeholders' Acceptability of Pharmacist-Led Screening in Community Pharmacies: A Systematic Review
    El-Den, Sarira
    Lee, Yee Lam Elim
    Gide, Duha N.
    O'Reilly, Claire L.
    [J]. AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2022, 63 (04) : 636 - 646
  • [3] Multifaceted Pharmacist-led Interventions in the Hospital Setting: A Systematic Review
    Skjot-Arkil, Helene
    Lundby, Carina
    Kjeldsen, Lene Juel
    Skovgards, Diana Mark
    Almarsdottir, Anna Birna
    Kjolhede, Tue
    Duedahl, Tina Hoff
    Pottegard, Anton
    Graabaek, Trine
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 123 (04) : 363 - 379
  • [4] PHARMACIST-LED INTERVENTIONS FOR REDUCING HEALTH DISPARITIES: A SYSTEMATIC REVIEW
    Mey, S., V
    Patel, S.
    Cordone, C. N.
    Lukman, G.
    Sung, J. H.
    Wang, A.
    Chan, A.
    Cadiz, C. L.
    Hurley-Kim, K.
    Wisseh, C.
    Knox, E.
    Lee, J. Y. C.
    Ozaki, A.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S497 - S497
  • [5] Pharmacist-led optimization of heart failure medications: A systematic review
    Cao, Vivien F. S.
    Cowley, Emily
    Koshman, Sheri L.
    MacGillivray, Jenny
    Sidsworth, Margaret
    Turgeon, Ricky D.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, 2021, 4 (07): : 862 - 870
  • [6] Exploring the heterogeneity in community pharmacist-led medication review studies - A systematic review
    Vogt, Cathrin J.
    Moecker, Robert
    Jacke, Christian O.
    Haefeli, Walter E.
    Seidling, Hanna M.
    [J]. RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2024, 20 (08): : 679 - 688
  • [7] Economic Evaluation of Pharmacist-Led Digital Health Interventions: A Systematic Review
    Park, Taehwan
    Kim, Hyemin
    Song, Seunghyun
    Griggs, Scott K.
    [J]. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (19)
  • [8] EFFECTS OF PHARMACIST-LED MOTIVATIONAL INTERVIEWING ON MEDICATION ADHERENCE: A SYSTEMATIC REVIEW
    Alongi, R., III
    Yang, H.
    Harmon, G.
    Kavookjian, J.
    [J]. RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2023, 19 (03): : 560 - 560
  • [9] Pharmacist-led interventions for the management of medication misuse and abuse: A systematic review
    Baum, Lindsay
    Badejo, Grace
    Chaboyer, Kevin
    Leong, Christine
    [J]. JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2017, 57 (03) : 297 - 298
  • [10] Pharmacist-led medication review in community settings: An overview of systematic reviews
    Jokanovic, Natali
    Tan, Edwin C. K.
    Sudhakaran, Sreeja
    Kirkpatrick, Carl M.
    Dooley, Michael J.
    Ryan-Atwood, Taliesin E.
    Bell, J. Simon
    [J]. RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2017, 13 (04): : 661 - 685